Specification: Each tablet contains 150 mg of ACC007, 300 mg of lamivudine and 300 mg of tenofovir fumarate

2 trials

Sponsors

Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Beijing Ditan Hospital, Capital Medical University

Conditions

HIV/ADISHIV/AIDS

Phase 3

Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate Switching From a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors (NRTI) Plus a Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) to a Fixed Dose Combination(FDC) of ACC007 Versus Elvitegravir, in Virologically-Suppressed, HIV-1 Infected Participants&#

RecruitingChiCTR2100051605

Beijing Ditan Hospital, Capital Medical UniversityHIV/AIDS

Start: 2021-10-08Updated: 2022-03-14

Unknown Phase

Bioequivalence Study of Combination-ACC007 Tablets in Human

Active, not recruitingChiCTR1900028166

Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical SchoolHIV/ADIS

Start: 2021-01-10Updated: 2023-03-06

Related Papers

Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional study.

2025-09-30

Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF <i>versus</i> elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial.

2024-07-185 citations